Professional
Added to YB: 2024-05-24
Pitch date: 2024-05-23
ACHV [bullish]
Achieve Life Sciences, Inc.
-15.17%
current return
Author Info
Rogue Funds is a value-oriented hedge fund sharing in-depth analysis. Sign up for the newsletter.
Company Info
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom.
Market Cap
$149.2M
Pitch Price
$5.47
Price Target
30.00 (+547%)
Dividend
N/A
EV/EBITDA
-2.09
P/E
-2.00
EV/Sales
N/A
Sector
Biotechnology
Category
growth
Achieve Life Sciences: Nicotine Cessation Drug with Short-Term Multi-Bagger Potential
ACHV: Best-in-class smoking cessation drug, 2 successful P3 trials, pursing NDA in 1H '25 after safety study. Cytisinicline: 3-6x more effective than Chantix, safer with less nausea. $300M-$600M peak sales potential ($1B-$1.8B M.Cap at 3x sales). IP to 2040. Surprise FDA request for safety study led to dilution & discount; $64M cash + $60M warrants funds thru NDA. BoD additions signal likely buyout ahead of NDA. PT $12-$25 (135-385% upside).
Read full article (5 min)